# To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

> **NCT05253053** · PHASE1,PHASE2 · COMPLETED · sponsor: **TransThera Sciences (Nanjing), Inc.** · enrollment: 84 (actual)

## Conditions studied

- Advanced Solid Tumor
- Cholangiocarcinoma
- Biliary Tract Cancer
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Prostate Cancer
- Thyroid Cancer
- Gastric Cancer
- Gallbladder Cancer

## Interventions

- **DRUG:** TT-00420
- **DRUG:** Combination Product: Atezolizumab
- **DRUG:** Combination Product: Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT05253053
- **Lead sponsor:** TransThera Sciences (Nanjing), Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-13
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253053, "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05253053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*